Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents скачать в хорошем качестве

Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents

Dr. Cyrille Touzeau (University Hospital of Nantes—Nantes, France) reports on the evaluation of teclistamab’s (JNJ-64007957) safety and efficacy in RRMM Patients following exposure to other BCMA-targeted agents. Abstract Title: Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Following Exposure to Other B-Cell Maturation Antigen (BCMA)-Targeted Agents What is the purpose of this trial? Teclistamab (JNJ-64007957) is a T cell redirecting bispecific antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1 is an open-label, multicohort, phase 1/2 study evaluating teclistamab in patients with relapsed/ refractory multiple myeloma (RRMM) previously treated with ≥3 prior lines of therapy (LOT). An overall response rate (ORR) of 62.0% in patients with no prior anti-BCMA treatment (tx) was previously reported in a pooled analysis from phase 1 and phase 2 cohort A at a median follow-up (MFU) of 7.8 months. Here, efficacy and safety results of teclistamab from cohort C are reported, which enrolled patients who had prior exposure to anti-BCMA treatment. Conclusion: These preliminary results observed with serial targeting of BCMA with teclistamab following Antibody-drug conjugates (ADC) or CAR T treatment (tx) suggest a promising overall response rate (ORR) with early responses that deepen over time. Additionally, a well-tolerated safety profile was observed in patients treated with anti-BCMA tx. Doctor Bio: Dr. Cyrille Touzeau is a hematologist in the Hematology Department from the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment. His PhD was mainly focused on the activity of BH3 mimetics in multiple myeloma. Dr. Touzeau is currently a member of the Intergroupe Francophone du Myélome (IFM). Dr. Touzeau published more than 60 peer‐reviewed publications dedicated to multiple myeloma. _______________ Improving Lives | Finding the Cure In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.